What Artisan Biopharma does

Artisan Biopharma is a privately held for-profit LLC and Public Benefit Company founded in 2019 and headquartered in Hillsboro, Oregon, operating as a wholly-owned subsidiary of the Children's Cancer Therapy Development Institute (cc-TDI), a 501c3 nonprofit. The company develops targeted therapeutics for rare and aggressive pediatric cancers — primarily alveolar rhabdomyosarcoma, diffuse intrinsic pontine glioma (DIPG), and hepatoblastoma — using two proprietary technology platforms: a bioPROTAC system that deploys antibodies or nanobodies as molecular hooks to degrade intrinsically disordered transcription factors (such as PAX3:FOXO1) traditionally considered undruggable, and an Antibody Drug Conjugate (ADC) platform that selectively delivers cytotoxic payloads to tumor cells expressing specific receptors such as IL-13Rα2 in DIPG. Its lead programs are the bioPROTAC for rhabdomyosarcoma (targeting PAX3:FOXO1 fusion proteins with first-in-human projected for Q1 2028) and an ADC for DIPG (in IND-enabling studies with projected completion in 2026), with a third ADC program for hepatoblastoma in preclinical validation.

The company pursues a dual-use drug development model in which each pediatric oncology asset is paired with a larger adult-market indication — rhabdomyosarcoma with adult-onset diabetes, DIPG with adult glioblastoma, and hepatoblastoma with adult ovarian cancer — to create commercial viability for assets that would otherwise lack sufficient standalone market economics. Business activity currently centers on capital formation from impact investors and foundations, royalty-sharing frameworks, and licensing/stewardship arrangements where Artisan provides pediatric clinical trial stewardship for pharmaceutical companies seeking RACE Act compliance. The company has no commercialized products and no disclosed revenue. Distribution is conducted through direct partnership outreach to pharma (via [email protected]), impact-investor channels, and collaborative frameworks with foundations and patient advocacy organizations. Pipeline advancement is supported by collaborations including the Children's Oncology Group (where Scientific Director Charles Keller co-chairs CNS-DVL), NIH-funded NCATS drug repurposing programs, and the Spatial Profiling and Annotation Centre of Excellence (SPACE) at Cambridge University for DIPG tumor microenvironment research.

Name

Artisan Biopharma

Legal name

Artisan Biopharma

Website

https://artisanbio.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Artisan Biopharma is a pediatric oncology biotech developing bioPROTAC and ADC therapies for rhabdomyosarcoma, DIPG, and hepatoblastoma, using a dual-use model that pairs each pediatric indication with an adult-market application to improve commercial viability.

Ownership category

akta.pro rank

Product category

Pediatric Oncology Drug Development

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Rare Oncology & Hematologic Malignancy Therapies (HLAIAIAC)

akta.pro secondary industries

Rare Pediatric & Congenital Disorder Therapies (HLAIAIAN), Oncology Specialty Pharmaceuticals (HLAIACAA)

Keywords

• Pediatric oncology therapeutics
• Targeted protein degradation
• Antibody drug conjugates
• Cancer drug development
• Protein degradation platform

Headquarters

HQ city

Hillsboro

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Investment Capital: Artisan Biopharma raises capital from impact investors interested in dual-use drug development combining pediatric cancer applications with adult market opportunities. The dual-use strategy creates a traditional biotech investment profile where commercial adult indications provide primary value drivers, while pediatric applications address urgent unmet needs.
2. Royalty-Sharing Programs: Collaborative funding arrangements with foundations where proceeds from successful drug development flow back through royalty-sharing frameworks tied to specific programs or therapeutic areas, creating sustainable funding loops for reinvestment in further research.
3. Licensing and Stewardship Services: Artisan licenses intellectual property from cc-TDI and other research entities, and in-licenses drugs from pharmaceutical companies for pediatric repurposing. The company provides stewardship services for clinical trials, offering pharmaceutical companies a mechanism to undertake pediatric clinical trials as required by the RACE Act.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Artisan Biopharma develops targeted therapeutics for pediatric cancers using two proprietary platforms: bioPROTAC (antibody/nanobody-based protein degradation for "undruggable" transcription factors) and ADC (Antibody Drug Conjugate for selective tumor cell delivery). The company operates a dual-use drug development strategy, creating therapies that target both pediatric cancers (rhabdomyosarcoma, DIPG, hepatoblastoma) and adult indications (diabetes, glioblastoma, ovarian cancer) to enable commercial viability while addressing urgent unmet pediatric needs.

Product overview

Artisan Biopharma is a for-profit subsidiary of cc-TDI (Children's Cancer Therapy Development Institute) advancing pediatric oncology drug development through two proprietary technology platforms: bioPROTAC (antibody/nanobody-based targeted protein degradation) and ADC (Antibody Drug Conjugate). The company operates a dual-use strategy, developing therapies for rare pediatric cancers that also have secondary applications in larger adult indications to improve commercial viability. Current pipeline includes bioPROTAC for rhabdomyosarcoma (first-in-human projected Q1 2028) and diabetes, ADC for DIPG/adult glioblastoma (IND-enabling studies 2026), and ADC for hepatoblastoma/adult ovarian cancer (preclinical).

Differentiator

Problem solved

Functional benefit

Products and services

• bioPROTAC

Quantifiable outcome

• PAX3:FOXO1 knockdown improves chemotherapy and radiation sensitivity and reduces tumor re-establishment in ARMS models
• +2 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Spatial Profiling and Annotation Centre of Excellence (SPACE) at Cambridge UniversitycoreStrategic or Co-development PartnerArtisan Biopharma is collaborating with Dr. Dario Bressan at the Spatial Profiling and Annotation Centre of Excellence (SPACE) at Cambridge University in a study of IL-13 Receptor and co-target expression in the tumor microenvironment of DIPG. This research supports the company's ADC development program for diffuse intrinsic pontine glioma by investigating target expression patterns in the tumor microenvironment.
• Children's Cancer Therapy Development Institute (cc-TDI)coreStrategic or Co-development PartnerArtisan Biopharma is wholly-owned by cc-TDI, a 501c3 non-profit organization. The company licenses intellectual property from cc-TDI and leverages over 24 years of pediatric cancer research expertise. cc-TDI has spent more than a decade devoted to research of rare, aggressive, and difficult-to-treat pediatric cancers, supported by NIH and foundation-level grants.
• Industry and Academic PartnersminorStrategic or Co-development PartnerArtisan Biopharma collaborates with industry and academic partners in sarcoma, brain tumors, and other pediatric cancer research, as well as prominent UK Universities. These partnerships support the company's mission to advance pediatric cancer drug development through shared expertise and resources.
• Children's Oncology Group (COG)minorStrategic or Co-development Partnercc-TDI was built to complement the Children's Oncology Group and related clinical trial networks while synergizing with both academic laboratories and pharma R&D laboratories. Charles Keller serves on the CNS-DVL committee and STS committee within COG.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• ImmunoGen (AbbVie): Oncology company specializing in ADC technology combining antibodies with cytotoxic payloads. Comparable because it is a leading ADC platform company, validating and competing in the same antibody-drug conjugate modality Artisan is advancing for DIPG and hepatoblastoma.
• BridgeBio Pharma: Commercial-stage biotech developing medicines for genetic diseases and cancers with clear genetic drivers, frequently in small patient populations. Comparable because it pursues indication-focused drug development in rare and underserved populations, paralleling Artisan's rare pediatric oncology focus.
• Kymera Therapeutics: Clinical-stage biotech developing targeted protein degradation therapies using heterobifunctional small molecules against oncology targets. Comparable because it is a direct competitor in the protein degradation space with oncology focus, validating the platform category Artisan is pursuing with its bioPROTAC modality.
• Day One Biopharmaceuticals: Pediatric oncology-focused biotech developing targeted therapies for rare childhood cancers, including brain tumors. Comparable because it pursues the same dual-use pediatric-plus-adult strategy and targets similar underserved pediatric oncology indications with small patient populations.
• Arvinas: Clinical-stage biotech pioneering targeted protein degradation (PROTAC) technology to address 'undruggable' disease-driving proteins. Comparable because it pursues protein-degradation-based therapeutics against oncogenic targets, the same modality foundation as Artisan's bioPROTAC platform.
• Y-mAbs Therapeutics: Pediatric oncology biotech commercializing antibody-based therapeutics for childhood cancers including brain tumors. Comparable because it uses antibody-based platforms (ADCs and bispecifics) targeting pediatric indications with limited treatment options, mirroring Artisan's ADC development model.
• Foghorn Therapeutics: Clinical-stage biotech developing medicines that target the chromatin regulatory system, including transcription factors implicated in cancer. Comparable because it specifically targets transcription-factor-driven oncology programs, the same 'undruggable' protein class Artisan's bioPROTAC is engineered to address.

Emerging players

• Recursion Pharmaceuticals: Tech-enabled drug discovery company combining AI/ML with high-throughput biology to advance rare disease and oncology programs. Comparable as an emerging player pursuing pipeline expansion in rare and underserved disease areas using a non-traditional development model similar to Artisan's partnership-driven approach.

Broad incumbents

• AbbVie: Global biopharmaceutical company with major oncology, immunology, and ADC (via ImmunoGen) franchises. Comparable as a broad incumbent where Artisan's CSO previously held a Distinguished Research Fellow role, and which pursues overlapping ADC and oncology protein-degradation strategies.
• Daiichi Sankyo: Global pharmaceutical company and ADC platform leader (Enhertu, Datroway) with deep oncology pipeline including brain tumor programs. Comparable as a broad incumbent in ADC oncology that competes for the same target indications Artisan pursues (including adult glioblastoma overlap).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/artisanbiopharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Artisan Biopharma